The Federal Institute for Drugs and Medical Devices, the German regulatory authority, has approved Helix BioPharma's clinical trial application for a European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.
The company requires a strategic partner, additional funding, and interferon alpha-2b raw material support so as to begin any such trial.
Helix, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, at present do not have an estimated timeline for initiation of such trial.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/german-regulatory-authority-approves-helix-trial-of-topical-interferon-alpha-2b-210512
